The Rhode Island Life Science Hub and Cognito Therapeutics have established the Rhode Island Brain Health Collaboratory, a statewide platform to evaluate and deploy Cognito's Spectris neuromodulation technology across health systems and research institutions. It is the third such regional collaboratory in Cognito's network, following partnerships in West Virginia and with Ochsner Health. The company states that Spectris AD holds FDA Breakthrough Device designation and that pivotal HOPE trial results are expected later in 2026.
Key Points
- Statewide collaboratory formed to deploy and study Spectris neuromodulation
- Third regional site in Cognito's national brain health network
- Pivotal HOPE trial results anticipated later in 2026
Longevity Analysis
Non-invasive neuromodulation represents a shift toward entraining neural activity rather than targeting a single molecular pathway in neurodegeneration, with implications for how the aging brain clears metabolic waste, sustains energy production, and maintains network coherence. The collaboratory model matters as much as the device: embedding a protocol within health systems, academic centers and community infrastructure addresses the implementation gap that separates promising intervention data from sustained daily use. Confirmation awaits the pivotal trial readout, which will determine whether measured cognitive and functional outcomes justify the deployment architecture now being built around it.
Original published by LT Wire.